These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 15145966)

  • 1. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal.
    Dowell JA; Knebel W; Ludden T; Stogniew M; Krause D; Henkel T
    J Clin Pharmacol; 2004 Jun; 44(6):590-8. PubMed ID: 15145966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anidulafungin: a new echinocandin with a novel profile.
    Vazquez JA
    Clin Ther; 2005 Jun; 27(6):657-73. PubMed ID: 16117974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling.
    Groll AH; Mickiene D; Petraitiene R; Petraitis V; Lyman CA; Bacher JS; Piscitelli SC; Walsh TJ
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2845-55. PubMed ID: 11557479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anidulafungin versus fluconazole for invasive candidiasis.
    Reboli AC; Rotstein C; Pappas PG; Chapman SW; Kett DH; Kumar D; Betts R; Wible M; Goldstein BP; Schranz J; Krause DS; Walsh TJ;
    N Engl J Med; 2007 Jun; 356(24):2472-82. PubMed ID: 17568028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anidulafungin: a novel echinocandin.
    Vazquez JA; Sobel JD
    Clin Infect Dis; 2006 Jul; 43(2):215-22. PubMed ID: 16779750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine.
    Dowell JA; Stogniew M; Krause D; Henkel T; Weston IE
    J Clin Pharmacol; 2005 Feb; 45(2):227-33. PubMed ID: 15647416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis.
    Krause DS; Simjee AE; van Rensburg C; Viljoen J; Walsh TJ; Goldstein BP; Wible M; Henkel T
    Clin Infect Dis; 2004 Sep; 39(6):770-5. PubMed ID: 15472806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple-dose pharmacokinetics of anidulafungin during continuous venovenous haemofiltration.
    Leitner JM; Meyer B; Fuhrmann V; Saria K; Zuba C; Jäger W; Böhmdorfer M; Thalhammer F
    J Antimicrob Chemother; 2011 Apr; 66(4):880-4. PubMed ID: 21393208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anidulafungin: review of a new echinocandin antifungal agent.
    Raasch RH
    Expert Rev Anti Infect Ther; 2004 Aug; 2(4):499-508. PubMed ID: 15482216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications.
    Wagner C; Graninger W; Presterl E; Joukhadar C
    Pharmacology; 2006; 78(4):161-77. PubMed ID: 17047411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections.
    Benjamin DK; Driscoll T; Seibel NL; Gonzalez CE; Roden MM; Kilaru R; Clark K; Dowell JA; Schranz J; Walsh TJ
    Antimicrob Agents Chemother; 2006 Feb; 50(2):632-8. PubMed ID: 16436720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anidulafungin: a new echinocandin for candidal infections.
    de la Torre P; Reboli AC
    Expert Rev Anti Infect Ther; 2007 Feb; 5(1):45-52. PubMed ID: 17266452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis.
    Liu P; Mould DR
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4718-26. PubMed ID: 24913161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anidulafungin.
    Murdoch D; Plosker GL
    Drugs; 2004; 64(19):2249-58; discussion 2259-60. PubMed ID: 15456342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and pharmacokinetics of coadministered voriconazole and anidulafungin.
    Dowell JA; Schranz J; Baruch A; Foster G
    J Clin Pharmacol; 2005 Dec; 45(12):1373-82. PubMed ID: 16291712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections.
    Wang T; Chen S; Sun J; Cai J; Cheng X; Dong H; Wang X; Xing J; Dong W; Yao H; Dong Y
    J Antimicrob Chemother; 2014 Feb; 69(2):463-70. PubMed ID: 24084636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis.
    Gumbo T; Drusano GL; Liu W; Ma L; Deziel MR; Drusano MF; Louie A
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3695-700. PubMed ID: 16954319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anidulafungin--state of affairs from a clinical perspective.
    Vehreschild JJ; Kümmerle T; Karthaus M; Cornely OA
    Mycoses; 2007; 50 Suppl 1():38-43. PubMed ID: 17394608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology and antifungal properties of anidulafungin, a new echinocandin.
    Estes KE; Penzak SR; Calis KA; Walsh TJ
    Pharmacotherapy; 2009 Jan; 29(1):17-30. PubMed ID: 19113794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anidulafungin: is it a promising option in the treatment of pediatric invasive fungal infections?
    Tapısız A
    Expert Rev Anti Infect Ther; 2011 Mar; 9(3):339-46. PubMed ID: 21417873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.